Loading
A phase 1/2 trial of Elironrasib, Daraxonrasib, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting.
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC is a phase 1/2 interventional study registered as NCT06162221 by Revolution Medicines, Inc., with 616 participants planned, started 2024-01-18 and due to reach its primary completion in 2027-06. Interventions recorded: RMC-6291, RMC-6236, Pembrolizumab, Cisplatin, Carboplatin. Conditions listed: Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer. No results are recorded here; the registry entry is the source.
Shares Elironrasib, Revolution Medicines, Daraxonrasib, Cisplatin.
Shares Revolution Medicines, Pemetrexed, Cisplatin, Carboplatin.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Elironrasib, Revolution Medicines, Daraxonrasib, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Revolution Medicines, Daraxonrasib, Small-cell lung cancer, Non-small-cell lung cancer.